Predicine, Inc.

PredicineCARE™ played a critical role in identifying and enrolling patients with PIK3CA-mutated metastatic breast cancer in China, as highlighted in a new publication in The New England Journal of MedicineHAYWARD, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, is pleased to announce the publication of a landmark study in The New England Journal of Medicine (NEJM), demonstrating the clinical utility of the PredicineCARE™ liquid biopsy assay, which enabled identification and enrollment of PIK3CA-positive patients in China. The trial targets patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer (mBC). “The PI3Kα inhibitor-based regimen demonstrated a doubling of the progression-free survival with consistent benefit across all pre-specified patient subgroups,” said Dr Huiping Li, Chair of Department of Breast Oncology at Peking University Cancer Hospital & Institute, and one of the principal investigators of the study. “With the essential support of biomarker testing, this new first-line standard of care brings significant hope to breast cancer patients with PIK3CA mutations.” PredicineCARE™, a next-generation sequencing (NGS) assay, facilitated blood-based testing to detect genomic alterations among trial participants. PredicineCARE™ has received both FDA breakthrough device designation and New York State approval. “The publication of the New England Journal of Medicine demonstrates the clinical utility of PredicineCARE™ liquid biopsy assay in global clinical trials and personalized cancer care, exemplifying our commitment to robust, efficient and cost-effective early biomarker testing, helping identify patients who may benefit from targeted therapy” said Dr. Shidong Jia, Founder & CEO of Predicine. About PredicinePredicine is a global molecular insights company committed to advancing precision medicine in oncology and infectious disease diagnostics. Predicine is developing proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and disease progression. The Predicine portfolio includes blood, urine, and tissue based NGS assays designed for globally harmonized use in clinical trial, companion diagnostic (CDx) development, and commercialization. Through its business operations in Silicon Valley, Houston, Chicago and Shanghai, Predicine is partnering and collaborating with leading biopharma companies, institutions, and governments to support personalized healthcare on a global scale. Further information is available on the company websites, http://www.predicine.com. Stay in touch on LinkedIn or @Predicine on Twitter. Contact Information:Predicine, Inc.media@predicine.com

HAYWARD, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 9 ctDNA studies at ASCO 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and drug resistance mechanism studies. The forthcoming data represents significant potential for the practical application of Predicine’s cutting-edge liquid biopsy technology in personalized cancer care, clinical trials, and Companion Diagnostic (CDx) development. Numerous studies to be unveiled at the conference emphasize the distinct advantages of personalized PredicineBEACON™ and methylation-based PredicineALERT™ MRD underscoring the clinical utility of Predicine’s liquid biopsy portfolio in biomarker discovery, therapy selection, MRD monitoring, and drug resistance mechanism analyses. Predicine Oral Presentation PresenterTitle Product Saturday, June 1 | 1:30 pm – 4:30 pm Jian LiA phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results.PredicineCARE™ Full List of Predicine PresentationsAbstract Poster TitleProductSaturday, June 1 | 9:00 am – 12:00 pm2053352Glioma monitoring via longitudinal intracranial cerebrospinal fluid cell-free DNA.PredicineCARE™PredicineSCORE™ Sunday, June 2 | 9:00 pm – 12:00 pm260887Clinical utility of an ultra-sensitive ctDNA NGS assay for the detection and monitoring in HR-positive, HER2-negative breast cancer.PredicineCARE™ Ultra e16604-Non-invasive detection of urothelial carcinoma through ensembled methylation profiles and fragmentomic patterns in urinary cell-free DNA.PredicineEPIC™ e16602-Real-world study of urine-based NGS liquid biopsy in organ preservation therapy of muscle-invasive bladder cancer (MIBC).PredicineBEACON™PredicineALERT™ e12654-Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy.PredicineBEACON™e13076-Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).PredicineCARE™ Monday, June 3 | 1:30 pm – 4:30 pm8587451High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.PredicineEPIC™4600295Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC).PredicineBEACON™ Visit Predicine Booth #14105 at ASCO 2024! Participate in conversations surrounding these groundbreaking studies and explore collaboration opportunities. Our liquid biopsy solutions are designed to be accessible and affordable for global clinical trials, CDx development, and patient testing across the US, EU, China, and the rest of world. Click here to arrange an in-person meeting with the Predicine team at ASCO booth #14105 or click here to schedule an online meeting. To learn more about Predicine, please see our corporate brochure, product portfolio, and visit our website. About Predicine Predicine is a leading molecular insights company committed to advancing precision medicine in oncology. Predicine has developed a proprietary cell-free DNA and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The Predicine portfolio comprises state-of-the-art blood, urine, and tissue-based Next-Generation Sequencing (NGS) assays designed for harmonized global use in research, clinical development, companion diagnostic (CDx) development, and patient testing. With operational hubs in Silicon Valley, Houston, Chicago, and Shanghai, Predicine collaborates with leading biopharma companies, institutions, and governments in personalized healthcare on a global scale. For more information, please visit us on http://www.predicine.com and follow us on LinkedIn or Twitter (X). Contact Information:Predicine, Inc.media@predicine.com

HAYWARD, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, enabling tumor profiling. The PredicineCARE™ NGS assay was granted Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) on August 23, 2022. This newly introduced PredicineCARE™ NGS kit integrates a comprehensive, state-of-the-art NGS assay capable of detecting point mutations, indels, fusions, amplifications, and deletions in key cancer-associated genes. It harnesses cell-free DNA (cfDNA) from liquid biopsy samples such as blood and urine, along with genomic DNA from FFPE tissues. “We are delighted to present the PredicineCARE™ NGS Kit specifically tailored to address the evolving needs of pharmaceutical companies and testing laboratories seeking decentralized lab testing options,” said Dr. Shidong Jia, Predicine’s Founder, Chairman, and CEO. “Predicine’s centralized global lab network coupled with the decentralized kitted offering provides a standardized approach to enable tumor profiling on a global scale.” About Predicine Predicine is a leading molecular insights company committed to advancing precision medicine in oncology. Predicine has developed a proprietary cell-free DNA and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The Predicine portfolio comprises state-of-the-art blood, urine, and tissue-based Next-Generation Sequencing (NGS) assays designed for harmonized global use in research, clinical development, companion diagnostic (CDx) development, and patient testing. With operational hubs in Silicon Valley, Houston, Chicago, and Shanghai, Predicine collaborates with leading biopharma companies, institutions, and governments in personalized healthcare on a global scale. For more information, please visit us on and follow us on LinkedIn or Twitter (X). Contact Information: Predicine, Inc. media@predicine.com A photo accompanying this announcement is available at PredicineCARE™ Research-use-only (RUO) next-generation sequencing (NGS) kit